<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01622725</url>
  </required_header>
  <id_info>
    <org_study_id>2012/223</org_study_id>
    <nct_id>NCT01622725</nct_id>
  </id_info>
  <brief_title>Primary and Secondary Ventral Hernia Repair Using Long-term Resorbable Versus Non-resorbable Large Pore Synthetic Mesh.</brief_title>
  <acronym>TIGR</acronym>
  <official_title>Recurrence Rate After Primary and Secondary Ventral Hernia Repair Using Long-term Resorbable Versus Non-resorbable Large Pore Synthetic Mesh.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novus Scientific</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since abdominal wall hernia repair is currently performed with the use of a mesh, side&#xD;
      effects associated with the mesh are frequently reported during long term follow-up. These&#xD;
      side effects are related to shrinkage of the mesh, adhesions to the bowl, pain, and&#xD;
      inflammation of the skin and bowl. To reduce or prevent these effects, a fully resorbing mesh&#xD;
      has been developed, which provides sufficient support and strength to allow efficient&#xD;
      recovery of the abdominal wall, but also disappear from your body in three years time, so&#xD;
      that you no longer have any synthetic material in your body. Previous resorbing meshes also&#xD;
      disappeared but over a much shorter period of time, so that the hernia was insufficiently&#xD;
      healed, with recurrence as a result.&#xD;
&#xD;
      The TIGR™ mesh (the resorbable mesh used in the study) is in principle a synthetic mesh, made&#xD;
      of two commonly used polymers, however it will retain 50% of its initial strength after six&#xD;
      months. This in theory is enough to provide support of the collagen healing process during&#xD;
      the initial wound-healing phase, but also to support the transition of initial collagen to&#xD;
      functional collagen.&#xD;
&#xD;
      The aim of this study is to compare TIGR™ with large pore mesh used in the repair of the&#xD;
      anterior abdominal wall repair (incisional hernia, umbilical hernia, etc..Inguinal hernias&#xD;
      are not part of the study).&#xD;
&#xD;
      Therefore the patients will be divided into two groups, one group will be treated with a&#xD;
      resorbing mesh, the other group will be treated with a permanent mesh. Otherwise there will&#xD;
      be no difference in the medication or the surgical techniques used.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence rate at 3 years post-surgery.</measure>
    <time_frame>3 years post-surgery</time_frame>
    <description>Clinical evaluation and ultrasound evaluation after 3 years post-surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound Morbidity 4 weeks post-surgery.</measure>
    <time_frame>4 weeks post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and discomfort after 1 year post-surgery.</measure>
    <time_frame>After 1 year post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and discomfort after 3 years post-surgery.</measure>
    <time_frame>After 3 years post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate by clinical examination 1 year post-surgery.</measure>
    <time_frame>After 1 year post-surgery.</time_frame>
    <description>Clinical Examination to determine the recurrence rate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Primary and Secondary Ventral Hernia</condition>
  <arm_group>
    <arm_group_label>Resorbable mesh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long-term resorbable mesh implanted to treat primary and secondary ventral hernia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-resorbable mesh</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-resorbable synthetic mesh implanted to treat primary and secondary ventral hernia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placing the resorbable mesh</intervention_name>
    <description>Surgery for primary and secondary ventral hernia repair with placing of resorbable mesh.</description>
    <arm_group_label>Resorbable mesh</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Non-resorbable synthetic mesh.</intervention_name>
    <description>Surgery for primary and secondary ventral hernia repair with placing of non-resorbable synthetic mesh.</description>
    <arm_group_label>Non-resorbable mesh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary and secondary ventral hernia&#xD;
&#xD;
               -  less than 20 cm in length&#xD;
&#xD;
               -  less than 6 cm in width&#xD;
&#xD;
        Exclusion Criteria:&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederik Berrevoet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ul Jagalskiego</name>
      <address>
        <city>Wejherowo</city>
        <zip>84-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de 12 Octobre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 15, 2012</study_first_submitted>
  <study_first_submitted_qc>June 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2012</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ventral hernia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Ventral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

